- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Fremanezumab – November 2019
Fremanezumab: Injection 225 mg in 1.5 mL pre-filled syringe; Ajovy®
Last updated
20 March 2020